344 related articles for article (PubMed ID: 17497647)
1. Endogenous secretory receptor for advanced glycation endproducts as a novel prognostic marker in chondrosarcoma.
Takeuchi A; Yamamoto Y; Tsuneyama K; Cheng C; Yonekura H; Watanabe T; Shimizu K; Tomita K; Yamamoto H; Tsuchiya H
Cancer; 2007 Jun; 109(12):2532-40. PubMed ID: 17497647
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical expression of estrogen receptors in chondrosarcomas and enchondromas.
Grifone TJ; Haupt HM; Podolski V; Brooks JJ
Int J Surg Pathol; 2008 Jan; 16(1):31-7. PubMed ID: 18203781
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of A disintegrin and metalloproteinase 28 is correlated with high histologic grade in conventional chondrosarcoma.
Matsuura S; Oda Y; Matono H; Izumi T; Yamamoto H; Tamiya S; Iwamoto Y; Tsuneyoshi M
Hum Pathol; 2010 Mar; 41(3):343-51. PubMed ID: 19896699
[TBL] [Abstract][Full Text] [Related]
4. Minichromosome maintenance protein (MCM6) in low-grade chondrosarcoma: distinction from enchondroma and identification of progressive tumors.
Helfenstein A; Frahm SO; Krams M; Drescher W; Parwaresch R; Hassenpflug J
Am J Clin Pathol; 2004 Dec; 122(6):912-8. PubMed ID: 15539383
[TBL] [Abstract][Full Text] [Related]
5. Prognostic relevance of cell biologic and biochemical features in conventional chondrosarcomas.
Aigner T; Müller S; Neureiter D; Illstrup DM; Kirchner T; Björnsson J
Cancer; 2002 Apr; 94(8):2273-81. PubMed ID: 12001127
[TBL] [Abstract][Full Text] [Related]
6. PAS inclusions, immunoreactive tenascin and proliferative activity in low-grade chondrosarcomas.
Ranty ML; Michot C; Le Pessot F; Hellot MF; Biga N; Dujardin FH; Simonet J; Billerey C; Metayer J
Pathol Res Pract; 2003; 199(1):29-34. PubMed ID: 12650515
[TBL] [Abstract][Full Text] [Related]
7. Expression of leukemia inhibitory factor by cartilage-forming tumors of bone: an immunohistochemical study.
Gouin F; Moreau A; Couillaud S; Guicheux J; Passuti N; Godard A; Heymann D
J Orthop Res; 1999 Mar; 17(2):301-5. PubMed ID: 10221849
[TBL] [Abstract][Full Text] [Related]
8. Molecular analysis of the INK4A/INK4A-ARF gene locus in conventional (central) chondrosarcomas and enchondromas: indication of an important gene for tumour progression.
van Beerendonk HM; Rozeman LB; Taminiau AH; Sciot R; Bovée JV; Cleton-Jansen AM; Hogendoorn PC
J Pathol; 2004 Mar; 202(3):359-66. PubMed ID: 14991902
[TBL] [Abstract][Full Text] [Related]
9. cDNA expression profiling of chondrosarcomas: Ollier disease resembles solitary tumours and alteration in genes coding for components of energy metabolism occurs with increasing grade.
Rozeman LB; Hameetman L; van Wezel T; Taminiau AH; Cleton-Jansen AM; Hogendoorn PC; Bovée JV
J Pathol; 2005 Sep; 207(1):61-71. PubMed ID: 16007578
[TBL] [Abstract][Full Text] [Related]
10. Usefulness of cytofluorometric DNA ploidy analysis in distinguishing benign cartilaginous tumors from chondrosarcomas.
Kusuzaki K; Murata H; Takeshita H; Hirata M; Hashiguchi S; Tsuji Y; Nakamura S; Ashihara T; Hirasawa Y
Mod Pathol; 1999 Sep; 12(9):863-72. PubMed ID: 10496594
[TBL] [Abstract][Full Text] [Related]
11. Expression of c-met proto-oncogene product (c-MET) in benign and malignant bone tumors.
Naka T; Iwamoto Y; Shinohara N; Ushijima M; Chuman H; Tsuneyoshi M
Mod Pathol; 1997 Aug; 10(8):832-8. PubMed ID: 9267827
[TBL] [Abstract][Full Text] [Related]
12. Endogenous secretory receptor for advanced glycation end-products and cardiovascular disease in end-stage renal disease.
Nishizawa Y; Koyama H
J Ren Nutr; 2008 Jan; 18(1):76-82. PubMed ID: 18089449
[TBL] [Abstract][Full Text] [Related]
13. Assessment of interobserver variability and histologic parameters to improve reliability in classification and grading of central cartilaginous tumors.
Eefting D; Schrage YM; Geirnaerdt MJ; Le Cessie S; Taminiau AH; Bovée JV; Hogendoorn PC;
Am J Surg Pathol; 2009 Jan; 33(1):50-7. PubMed ID: 18852676
[TBL] [Abstract][Full Text] [Related]
14. Receptor for advanced glycation end products (RAGE) is important in the prediction of recurrence in human oral squamous cell carcinoma.
Sasahira T; Kirita T; Bhawal UK; Yamamoto K; Ohmori H; Fujii K; Kuniyasu H
Histopathology; 2007 Aug; 51(2):166-72. PubMed ID: 17593216
[TBL] [Abstract][Full Text] [Related]
15. Absence of IHH and retention of PTHrP signalling in enchondromas and central chondrosarcomas.
Rozeman LB; Hameetman L; Cleton-Jansen AM; Taminiau AH; Hogendoorn PC; Bovée JV
J Pathol; 2005 Mar; 205(4):476-82. PubMed ID: 15685701
[TBL] [Abstract][Full Text] [Related]
16. PTHrP and Bcl-2: essential regulatory molecules in chondrocyte differentiation and chondrogenic tumors.
Amling M; Pösl M; Hentz MW; Priemel M; Delling G
Verh Dtsch Ges Pathol; 1998; 82():160-9. PubMed ID: 10095428
[TBL] [Abstract][Full Text] [Related]
17. Chondrosarcoma is not characterized by detectable telomerase activity.
Bovée JV; van Den Broek LJ; Cleton-Jansen AM; Hogendoorn PC
J Pathol; 2001 Mar; 193(3):354-60. PubMed ID: 11241416
[TBL] [Abstract][Full Text] [Related]
18. D2-40 functions as an effective chondroid marker distinguishing true chondroid tumors from chordoma.
Huse JT; Pasha TL; Zhang PJ
Acta Neuropathol; 2007 Jan; 113(1):87-94. PubMed ID: 17021752
[TBL] [Abstract][Full Text] [Related]
19. Identification of mouse orthologue of endogenous secretory receptor for advanced glycation end-products: structure, function and expression.
Harashima A; Yamamoto Y; Cheng C; Tsuneyama K; Myint KM; Takeuchi A; Yoshimura K; Li H; Watanabe T; Takasawa S; Okamoto H; Yonekura H; Yamamoto H
Biochem J; 2006 May; 396(1):109-15. PubMed ID: 16503878
[TBL] [Abstract][Full Text] [Related]
20. The receptor for advanced glycation endproducts and its ligands in patients with myasthenia gravis.
Moser B; Bekos C; Zimprich F; Nickl S; Klepetko W; Ankersmit J
Biochem Biophys Res Commun; 2012 Mar; 420(1):96-101. PubMed ID: 22405771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
